EGFR and neoplasm: Patients with RAS mutant-type or right-sided mCRC cannot benefit from cetuximab, and only the patients with both RAS wild-type and left-sided mCRC are candidates for anti-EGFR therapy, while bevacizumab shows efficacy regardless of the tumor location or RAS mutation status8,17–20.